Unregulated online sources, bulk-compounded products, and non-prescription GLP-1 medications should always be avoided due to significant risks related to dosing accuracy, contamination, and patient safety
Researching an off-ramp Clinicians have a body of research on starting GLP-1s, but theres less evidence on how to stop them, Biermann says
Nagai A, Kim W K, Lee HJ, et al
We prescribe patients scheduled doses, increasing incrementally, so their bodies can adjust gradually. Doses start low, and often increase over time Patients generally want to meet their goal dose quickly, to see the most progress
(11) T J Smith (2010) Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases
Laura has been an educational speaker for Allergan pharmaceuticals and has collaborated on numerous focus groups for Galderma and Allergan pharmaceuticals for medications